Researchers at OHSU have developed a first-of-its-kind method to predict cancer patient survival using advanced molecular data from individual cells.
The new approach pinpoints harmful and helpful cell populations that can drive disease progression.
#OHSUResearch:
The procedure (Hepzato percutaneous hepatic perfusion) is limited to a rare form of cancer called uveal melanoma, which begins in the eye but can metastasize to other organs, most commonly the liver.
Learn more about this new cancer treatment procedure:
“The Evolving Practice of Personalized Medicine”
Join us as Dr. Monica Bertagnolli addresses personalized medicine as the keynote speaker for #ResearchWeek.
🗓️ May 4
⏰ 12 PM
📍 Webex
“These tools let us see critical cancer‑related processes happening live, at the very small scale where key decisions are made inside cells.”
- Dr. Cathy Galbraith on new imaging tools that help cancer researchers see inside living cells:
Leading the way.
OHSU is the first in the PNW to perform a procedure that floods cancerous cells in the liver with high doses of a potent chemotherapy drug and then removes it with a surgical trap before it can circulate through the rest of the body:
“Without this technique, this would have been a major operation with full exposure of the liver.
This new technique is truly a revolutionary difference in how this treatment can be performed.”
- Dr. Khashayar Farsad on a new cancer treatment procedure:
“The NIH is prioritizing more human‑relevant models.
These devices allow us to generate that complexity in the lab and get important questions we cannot study in patients.”
- Dr. Luiz Bertassoni on funding to build the next generation ‘organs on chips’ for bone-related cancers:
🔥 Is it hot in here? 🔥
Instead of using a surgical procedure, researchers at OHSU have discovered a new way to treat #Melanoma: Heat.
Learn more (via KGW): https://bit.ly/3PXP5cZ
New #OHSUResearch shows a breakthrough in microscopy tools, expanding how cancer biology labs study the inner workings of living cells.
The research introduces a series of fluorescent dyes, making it easier to take ultra‑detailed images of living cells:
Our Precision Biofabrication Hub has been awarded more than $9M from the NIH for cutting-edge biofabrication research!
Researchers will develop "organs-on-a-chip" that recreate how cancers grow, spread, and respond to treatment within bone tissues:
“You can imagine hitting the cancer cell with a targeted drug while also reprogramming the immune environment around it.
That combination could be much more effective than either approach alone.”
- Dr. Katelyn Byrne on new #OHSUResearch:
Leading the way.
OHSU is the first in the PNW to perform a procedure that floods cancerous cells in the liver with high doses of a potent chemotherapy drug and then removes it with a surgical trap before it can circulate through the rest of the body:
The new dyes allow researchers to study processes closely tied to cancer, including how DNA is packaged and accessed, how genes are turned on and off, how cancer cells migrate, and how molecules organize themselves inside cells.
#OHSUResearch
New #OHSUResearch shows a breakthrough in microscopy tools, expanding how cancer biology labs study the inner workings of living cells.
The research introduces a series of fluorescent dyes, making it easier to take ultra‑detailed images of living cells:
Why haven’t many immunotherapies worked in #PancreaticCancer and what's a possible solution?
New #OHSUResearch suggests treatments may need to both turn on the immune system and overcome the tumor’s own ability to shut it down.
Learn more:
“These projects represent exactly what the Biofabrication Hub was created to do.
We are leveraging technologies developed here to study complex, aggressive cancers in ways that weren’t possible before.”
- Dr. Luiz Bertassoni on new NIH funding:
🔥 Is it hot in here? 🔥
Instead of using a surgical procedure, researchers at OHSU have discovered a new way to treat #Melanoma: Heat.
Learn more (via KGW): https://bit.ly/3PXP5cZ
🧡Brian Druker, president of @ohsuknight.bsky.social and the lead developer of the medication
🧡Jan Geissler, cofounder of the CML Advocates Network
🧡Pat Garcia-Gonzalez, Max CEO
🧡Paula Boultbee, Max board member
🧡Dr. Jerald Radich, Max board member, professor and clinical researcher at @fredhutch.org
Our Precision Biofabrication Hub has been awarded more than $9M from the NIH for cutting-edge biofabrication research!
Researchers will develop "organs-on-a-chip" that recreate how cancers grow, spread, and respond to treatment within bone tissues:
“You can imagine hitting the cancer cell with a targeted drug while also reprogramming the immune environment around it.
That combination could be much more effective than either approach alone.”
- Dr. Katelyn Byrne on new #OHSUResearch:
Why haven’t many immunotherapies worked in #PancreaticCancer and what's a possible solution?
New #OHSUResearch suggests treatments may need to both turn on the immune system and overcome the tumor’s own ability to shut it down.
Learn more:
“The goal is to intervene and prevent the progression to leukemia.
Considering RUNX1-FPD patients live in a pre-malignant state for many years, we see an opportunity to prevent or delay the development of leukemia."
- Dr. Agarwal on a clinical trial to prevent cancer in a rare genetic condition:
"I’m proud of the fact that the Knight Cancer Institute is a place that supports the innovation and creativity of scientists and health care professionals committed to ending cancer as we know it.”
- Dr. Brian Druker on receiving the Knight Lifetime Achievement Award:
Congratulations to Dr. Brian Druker on receiving the inaugural Knight Lifetime Achievement Award!
The award is named for Nike founder Phil Knight, a longtime supporter of the OHSU Knight Cancer Institute.
Learn more ⤵️
A new award will enable researchers to test an anti-inflammatory drug for patients at heightened risk of developing leukemia due to an inherited mutation in the RUNX1 gene.
The project builds upon an ongoing clinical trial at MD Anderson, with Dr. Agarwal serving as the lead investigator at OHSU:
“If you can understand the differences, you can target future therapies based on how cancer cells and normal cells work differently.”
- Dr. Jim Galbraith on new #OHSUResearch uncovering internal cell ‘trade winds’ that drive movement and repair:
Three people conversing while at a conference
A promotional image for the OHSU Knight Cancer Institute featuring a DNA strand in the background. Text highlights offerings such as interactive sessions, mock tumor board, updates in oncology, poster and networking sessions, and the opportunity for RN CE/CEU credits. Large text at the bottom reads, "Give Cancer Hell.
Mark your calendars for April 10, and join us for the annual @ohsuknight.bsky.social Symposium in Portland, OR! 🗓️
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts and earn up to 7.75 AMA PRA Category 1 Credits™:
“From the wall-size murals to beautiful views from each room as well as motion therapy rooms, Vista Pavilion will carry a legacy of compassionate healing for patients and families who come through the doors.”
- Former patient, Alan Lynn:
Drs. Sanjay Malhotra (L) and Shivaani Kummar (R) pose for an image while wearing their white research lab coats inside an OHSU facility.
📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://bit.ly/4qbMRU0
A new era of cancer care is here.
With the opening of the Vista Pavilion, OHSU is transforming how patients access life-saving treatment.
By bringing cutting-edge care together in one place, Vista helps ensure more patients can get the right care, at the right time, closer to home.
